JP7574184B2 - 悪性腫瘍の治療方法 - Google Patents

悪性腫瘍の治療方法 Download PDF

Info

Publication number
JP7574184B2
JP7574184B2 JP2021526910A JP2021526910A JP7574184B2 JP 7574184 B2 JP7574184 B2 JP 7574184B2 JP 2021526910 A JP2021526910 A JP 2021526910A JP 2021526910 A JP2021526910 A JP 2021526910A JP 7574184 B2 JP7574184 B2 JP 7574184B2
Authority
JP
Japan
Prior art keywords
day
cancer
phenyl
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526910A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020256096A1 (https=
JPWO2020256096A5 (https=
Inventor
一雄 木場
俊泰 下村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JPWO2020256096A1 publication Critical patent/JPWO2020256096A1/ja
Publication of JPWO2020256096A5 publication Critical patent/JPWO2020256096A5/ja
Application granted granted Critical
Publication of JP7574184B2 publication Critical patent/JP7574184B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021526910A 2019-06-21 2020-06-19 悪性腫瘍の治療方法 Active JP7574184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019115496 2019-06-21
JP2019115496 2019-06-21
PCT/JP2020/024113 WO2020256096A1 (ja) 2019-06-21 2020-06-19 悪性腫瘍の治療方法

Publications (3)

Publication Number Publication Date
JPWO2020256096A1 JPWO2020256096A1 (https=) 2020-12-24
JPWO2020256096A5 JPWO2020256096A5 (https=) 2022-03-16
JP7574184B2 true JP7574184B2 (ja) 2024-10-28

Family

ID=74040503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526910A Active JP7574184B2 (ja) 2019-06-21 2020-06-19 悪性腫瘍の治療方法

Country Status (8)

Country Link
US (1) US20220354858A1 (https=)
EP (1) EP3988175A4 (https=)
JP (1) JP7574184B2 (https=)
KR (1) KR20220024821A (https=)
AU (1) AU2020297166A1 (https=)
MA (1) MA56549A (https=)
TW (1) TWI856115B (https=)
WO (1) WO2020256096A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137870A1 (ja) 2011-04-06 2012-10-11 大鵬薬品工業株式会社 新規イミダゾオキサジン化合物又はその塩
WO2014007217A1 (ja) 2012-07-02 2014-01-09 大鵬薬品工業株式会社 イミダゾオキサジン化合物による抗腫瘍効果増強剤
WO2014203959A1 (ja) 2013-06-20 2014-12-24 大鵬薬品工業株式会社 ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法
WO2016136928A1 (ja) 2015-02-27 2016-09-01 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2657233T3 (da) 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP4093406A4 (en) * 2020-01-24 2024-02-28 Taiho Pharmaceutical Co., Ltd. IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137870A1 (ja) 2011-04-06 2012-10-11 大鵬薬品工業株式会社 新規イミダゾオキサジン化合物又はその塩
WO2014007217A1 (ja) 2012-07-02 2014-01-09 大鵬薬品工業株式会社 イミダゾオキサジン化合物による抗腫瘍効果増強剤
WO2014203959A1 (ja) 2013-06-20 2014-12-24 大鵬薬品工業株式会社 ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法
WO2016136928A1 (ja) 2015-02-27 2016-09-01 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BROWN, Jessica S. et al.，Maximising the potential of AKT inhibitors as anti-cancer treatments，Pharmacology & Therapeutics，2017年，Vol.172，pp.101-115

Also Published As

Publication number Publication date
TW202114691A (zh) 2021-04-16
US20220354858A1 (en) 2022-11-10
JPWO2020256096A1 (https=) 2020-12-24
WO2020256096A1 (ja) 2020-12-24
MA56549A (fr) 2022-04-27
TWI856115B (zh) 2024-09-21
AU2020297166A1 (en) 2022-02-17
EP3988175A4 (en) 2023-06-28
KR20220024821A (ko) 2022-03-03
EP3988175A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
JP7574184B2 (ja) 悪性腫瘍の治療方法
AU2017213541B2 (en) Combination therapy for the treatment of cancer
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
WO2023140329A1 (ja) がんの治療または予防用医薬
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
JP6911047B2 (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
JP2024001009A (ja) Ｐｉ３ｋ阻害剤であるｇｄｃ－００７７による癌の治療方法
TWI530287B (zh) 組合療法
TWI747868B (zh) 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
TW202602448A (zh) 用於乳癌治療之組合療法
JP2016519157A (ja) ガネテスピブを用いる特定癌の治療レジメン
JP7805285B2 (ja) ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
JP2024529430A (ja) がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ
RU2816126C2 (ru) Способ лечения злокачественной опухоли
JP2021138693A (ja) がんを処置するための方法
JP7445826B2 (ja) 固形腫瘍治療用医薬組成物
TW202508598A (zh) 癌症療法
WO2024255883A1 (zh) Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
HK40108632A (zh) 癌的治疗或预防用药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20211221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241016

R150 Certificate of patent or registration of utility model

Ref document number: 7574184

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150